Strategies to Reduce Errors Associated with 2-Component Vaccines.


Journal

Pharmaceutical medicine
ISSN: 1179-1993
Titre abrégé: Pharmaceut Med
Pays: New Zealand
ID NLM: 101471195

Informations de publication

Date de publication:
01 2021
Historique:
accepted: 05 10 2020
pubmed: 6 11 2020
medline: 29 10 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

The high incidence of error reports received by the US Food and Drug Administration (FDA) involving 2-component vaccines led to collaboration between the United States Pharmacopeia (USP) and the Institute for Safe Medication Practices (ISMP). This collaborating group sought to further understand errors associated with all 2-component vaccines (i.e. vaccine components provided by the manufacturer in physically separate containers) and to provide safe practice strategies for storing, preparing, dispensing, and administering these vaccines as intended. Fourteen available 2-component vaccines were identified. The ISMP National Vaccine Errors Reporting Program (VERP) and the FDA Vaccine Adverse Event Reporting System (VAERS) were searched from the initiation of each respective reporting system through December 31, 2019. The three vaccines with the most reported reconstitution errors in the VERP and VAERS are Menveo

Identifiants

pubmed: 33151497
doi: 10.1007/s40290-020-00362-9
pii: 10.1007/s40290-020-00362-9
pmc: PMC7846520
doi:

Substances chimiques

Bacterial Vaccines 0
Meningococcal Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Commentaires et corrections

Type : ErratumIn

Références

MMWR Morb Mortal Wkly Rep. 2016 Feb 19;65(6):161-2
pubmed: 26890604
Home Healthc Now. 2016 Apr;34(4):218-20
pubmed: 27023298
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):109-110
pubmed: 29370153
Drug Saf. 2006;29(5):385-96
pubmed: 16689555
BMC Med Inform Decis Mak. 2016 Mar 01;16:27
pubmed: 26926375
Vaccine. 2015 Jun 22;33(28):3171-8
pubmed: 25980429
MMWR Morb Mortal Wkly Rep. 2018 May 25;67(20):585-586
pubmed: 29795075
Drug Des Devel Ther. 2010 May 25;4:71-9
pubmed: 20531961
Glob J Health Sci. 2015 Dec 18;8(8):54510
pubmed: 27045415

Auteurs

Farzana Samad (F)

Institute for Safe Medication Practices, Horsham, PA, USA.

Samantha J Burton (SJ)

Institute for Safe Medication Practices, Horsham, PA, USA.

Diana Kwan (D)

United States Pharmacopeia, Rockville, MD, USA. dck@usp.org.

Noah Porter (N)

United States Pharmacopeia, Rockville, MD, USA.

Judy Smetzer (J)

Institute for Safe Medication Practices, Horsham, PA, USA.

Michael R Cohen (MR)

Institute for Safe Medication Practices, Horsham, PA, USA.

Jeanne Tuttle (J)

Department of Veterans Affairs, Pharmacy Benefits Management Services, Washington DC, USA.

Danial Baker (D)

College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.

Dennis E Doherty (DE)

Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, College of Medicine and Chandler Medical Center, Lexington, KY, USA.

Articles similaires

Humans United States Aged Cross-Sectional Studies Medicare Part C
Humans Emergency Service, Hospital Child Child, Preschool Infant
Humans Mobile Applications Hepatitis C Male Female

How Certification Exams Reflect Current Practice.

Tara L Myers, Sean DeGarmo, Marianne Horahan
1.00
Humans Certification Clinical Competence Education, Nursing, Continuing Adult

Classifications MeSH